Autoantibodies against TIF-1-γ and CADM-140 in Spanish patients with clinically amyopathic dermatomyositis (CADM): Clinical significance and diagnostic utility

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 3, 2015, Pages 482-489

  Cuesta Mateos, C ^a,b   Colom Fernandez B ^a   Portero Sainz, I ^a   Tejedor, R ^a   Garcia Garcia C ^a   Concha Garzon M J ^a   De Las Heras Alonso, M E ^c   Martinez M A ^d   Juarez, C ^d   Munoz Calleja C ^a  

^a Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^b IMS   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CADM 140 AUTOANTIBODY; CREATINE KINASE; NUCLEAR PROTEIN; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1 GAMMA; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1 GAMMA AUTOANTIBODY; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CADM-140 PEPTIDE, HUMAN; PEPTIDE; TIAF1 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; COHORT ANALYSIS; DERMATOMYOSITIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCLE BIOPSY; MUSCLE WEAKNESS; ONSET AGE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEX RATIO; SKIN BIOPSY; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; THYROID PAPILLARY CARCINOMA; AGED; IMMUNOLOGY; MIDDLE AGED; SPAIN;

ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; AUTOANTIBODIES; DERMATOMYOSITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PEPTIDES; SPAIN;

EID: 84923108323     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12591     Document Type: Article

References (48)

1. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-347.
2. Bohan A, Peter JB,. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-407.
3. Sato S, Kuwana M,. Clinically amyopathic dermatomyositis. Curr Opin Rheumatol 2013; 22: 639-643.
4. Betteridge ZE, Gunawardena H, McHugh NJ,. Pathogenic mechanisms of disease in myositis: autoantigens as clues. Curr Opin Rheumatol 2009; 21: 604-609.
5. Targoff IN, Mamyrova G, Trieu EP, et al,. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682-3689.
6. Targoff IN, Trieu E.P., Levy-Neto M., et al,. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-g) in dermatomyositis [abstract]. Arthritis Rheum 2006; 54 (Suppl): S518.
7. Kaji K, Fujimoto M, Hasegawa M, et al,. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46: 25-28.
8. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG,. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007; 66: 1345-1349.
9. Fujikawa K, Kawakami A, Kaji K, et al,. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol 2009; 38: 263-267.
10. Trallero-Araguas E, Labrador-Horrillo M, Selva-O'Callaghan A, et al,. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 2010; 89: 47-52.
11. Sato S, Hirakata M, Kuwana M, et al,. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571-1576.
12. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M,. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60: 2193-2200.
13. Kang EH, Nakashima R, Mimori T, et al,. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 2010; 11: 223.
14. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD,. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54: 597-613.
15. Gono T, Kawaguchi Y, Satoh T, et al,. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 2010; 49: 1713-1719.
16. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L,. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65: 25-34.
17. Cao H, Parikh TN, Zheng J,. Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis. Clin Rheumatol 2009; 28: 979-984.
18. Sontheimer RD,. Clinically amyopathic dermatomyositis: what can we now tell our patients? Arch Dermatol 2010; 146: 76-80.
19. Ghazi E, Sontheimer RD, Werth VP,. The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum. Clin Exp Rheumatol 2013; 31: 128-134.
20. Clarke JT, Werth VP,. Rheumatic manifestations of skin disease. Curr Opin Rheumatol 2009; 22: 78-84.
21. Nabatian AS, Bashir MM, Wysocka M, Sharma M, Werth VP,. Tumor necrosis factor alpha release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients. Arthritis Res Ther 2012; 14: R1.
22. Sontheimer RD,. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002; 46: 626-636.
23. Gilliam JN, Sontheimer RD,. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981; 4: 471-475.
24. Walling HW, Sontheimer RD,. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009; 10: 365-381.
25. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL,. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005; 84: 231-249.
26. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
27. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N,. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007; 56: 3132-3137.
28. Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, et al,. Anti-TIF1gamma antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays. Ann Rheum Dis 2012; 71: 993-996.
29. Fujimoto M, Hamaguchi Y, Kaji K, et al,. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012; 64: 513-522.
30. Bendewald MJ, Wetter DA, Li X, Davis MD,. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010; 146: 26-30.
31. Azuma K, Yamada H, Ohkubo M, et al,. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 2010; 21: 178-183.
32. Selva-O'Callaghan A, Trallero-Araguas E, Grau-Junyent JM, Labrador-Horrillo M,. Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol 2010; 22: 627-632.
33. Hamaguchi Y, Kuwana M, Hoshino K, et al,. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011; 147: 391-398.
34. Cao H, Pan M, Kang Y, et al,. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken) 2012; 64: 1602-1610.
35. Ye S, Chen XX, Lu XY, et al,. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 2007; 26: 1647-1654.
36. Grassi M, Capello F, Bertolino L, Seia Z, Pippione M,. Identification of granzyme B-expressing CD-8-positive T cells in lymphocytic inflammatory infiltrate in cutaneous lupus erythematosus and in dermatomyositis. Clin Exp Dermatol 2009; 34: 910-914.
37. Magro CM, Crowson AN,. The immunofluorescent profile of dermatomyositis: a comparative study with lupus erythematosus. J Cutan Pathol 1997; 24: 543-552.
38. Sontheimer RD,. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 2005; 4: 253-263.
39. Ghirardello A, Zampieri S, Tarricone E, et al,. Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity 2006; 39: 217-221.
40. Schulte-Pelkum J, Fritzler M, Mahler M,. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009; 8: 632-637.
41. Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ,. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997; 109: 32-40.
42. Kubo M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K,. Prevalence of 52-kd and 60-kd Ro/SS-A autoantibodies in Japanese patients with polymyositis/dermatomyositis. J Am Acad Dermatol 2002; 47: 148-151.
43. Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN,. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 1999; 12: 137-142.
44. Sontheimer RD, Maddison PJ, Reichlin M, Jordon RE, Stastny P, Gilliam JN,. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 1982; 97: 664-671.
45. Lee LA, Roberts CM, Frank MB, McCubbin VR, Reichlin M,. The autoantibody response to Ro/SSA in cutaneous lupus erythematosus. Arch Dermatol 1994; 130: 1262-1268.
46. Popovic K, Wahren-Herlenius M, Nyberg F,. Clinical follow-up of 102 anti-Ro/SSA-positive patients with dermatological manifestations. Acta Derm Venereol 2008; 88: 370-375.
47. Sun WC, Sun YC, Lin H, Yan B, Shi GX,. Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease. Br J Dermatol 2012; 167: 1236-1244.
48. Euwer RL, Sontheimer RD,. Amyopathic dermatomyositis: a review. J Invest Dermatol 1993; 100: 124S-127S.